Invasive Fungal Disease in Solid Organ and Hematopoietic Cell Transplant Recipients, United States
Transplant Infectious Disease · 2025
DOI: 10.1111/tid.70077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Jeremy A W Gold und 7 weiteren Autor:innen. Beteiligte Einrichtung: Mycotic Diseases Branch, CDC, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Invasive Fungal Infections, Organ Transplantation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS, NCEZID CDC HHS, ACL HHS.
Abstract (Originalsprache)
Background
Updated benchmark data on invasive fungal disease (IFD) in solid organ transplantation (SOT) and hematopoietic cell transplantation (HCT) recipients are necessary to increase clinical recognition and inform treatment and prevention strategies. We estimated IFD incidence and potential risk factors in transplant recipients in a large US commercial health insurance database.
Methods
We observed patients who received SOT or HCT during 2018–2022 until IFD development, disenrollment, or database end date (July 31, 2023). We calculated incidence (per 1000 person‐years) and time to IFD development, comparing demographic features and underlying conditions for IFD versus non‐IFD patients.
Results
Overall, 9143 patients received an SOT (5667 kidney, 2025 liver, 759 heart, 650 lung, 39 pancreas, 3 intestine), and 5693 patients received an HCT (3519 autologous, 2114 allogeneic, 60 unspecified type). Among SOT patients, 360 developed an IFD (incidence: 21.0 [per 1000 person‐years]). Mold infections had the highest incidence (7.1), followed by unspecified mycoses (3.9) and endemic mycoses (3.3). Among HCT patients, 292 developed an IFD (incidence: 28.5), with higher incidence among allogeneic (58.4) versus autologous (12.8) HCT recipients; among all HCT recipients, unspecified mycoses had the highest incidence (8.3), then pneumocystosis (7.6), and mold infections (6.7). Median time to IFD was 173.5 days for SOT recipients and 197.5 days for HCT recipients. IFD risk varied substantially by transplant type, region, and certain underlying conditions.
Conclusion
Our results suggest that IFDs remain an important cause of infection among SOT and HCT recipients, particularly later in the posttransplant period, and highlight the need for prevention strategies. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mycotic Diseases Branch, CDC, Atlanta, Georgia, USA.
- Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Stem Cell Transplant and Cellular Therapy, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
- McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA.
ORCID-Profile: Jeremy A W Gold
Förderung
- Intramural CDC HHS
- NCEZID CDC HHS
- ACL HHS
- NCATS NIH HHS
Zitieren
APA
Gold, J. A. W., Benedict, K., Sajewski, E., Chiller, T., Lyman, M., Toda, M., Little, J. S., & Ostrosky-Zeichner, L. (2025). Invasive Fungal Disease in Solid Organ and Hematopoietic Cell Transplant Recipients, United States. Transplant Infectious Disease. https://doi.org/10.1111/tid.70077
Vancouver
Gold JAW, Benedict K, Sajewski E, Chiller T, Lyman M, Toda M, et al. Invasive Fungal Disease in Solid Organ and Hematopoietic Cell Transplant Recipients, United States. Transplant Infectious Disease. 2025. doi:10.1111/tid.70077
BibTeX
@article{Gold2025,
author = {Gold, Jeremy A W and Benedict, Kaitlin and Sajewski, Elizabeth and Chiller, Tom and Lyman, Meghan and Toda, Mitsuru and Little, Jessica S and Ostrosky-Zeichner, Luis},
title = {Invasive Fungal Disease in Solid Organ and Hematopoietic Cell Transplant Recipients, United States},
journal = {Transplant Infectious Disease},
year = {2025},
doi = {10.1111/tid.70077}
}
EUVIMED